These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6809711)

  • 1. Current concepts in cancer: ovary--treatment for stages III and IV. The multimodal approach to the treatment of stage III ovarian carcinoma.
    Fuks Z; Rizel S; Anteby SO; Biran S
    Int J Radiat Oncol Biol Phys; 1982 May; 8(5):903-8. PubMed ID: 6809711
    [No Abstract]   [Full Text] [Related]  

  • 2. The sequential multiple modality treatment of ovarian cancer.
    Dembo AJ
    Radiother Oncol; 1985 Apr; 3(3):187-92. PubMed ID: 3923573
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiotherapeutic management of ovarian cancer.
    Dembo AJ
    Semin Oncol; 1984 Sep; 11(3):238-50. PubMed ID: 6435249
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 5. Current concepts in cancer: ovary--treatment for stages III and IV. Chemotherapy in advanced disease.
    Young RC; Myers CE; Ozols RF; Hogan WM
    Int J Radiat Oncol Biol Phys; 1982 May; 8(5):899-902. PubMed ID: 6809710
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress in the chemotherapy of ovarian cancer].
    Honetz N
    Wien Med Wochenschr; 1982 Jul; 132(13-14):319-24. PubMed ID: 6291259
    [No Abstract]   [Full Text] [Related]  

  • 7. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 8. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
    Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
    Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
    [No Abstract]   [Full Text] [Related]  

  • 12. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodality treatment of patients with advanced ovarian carcinoma.
    Pino y Torres JL; Bross DS; Hernandez E; Rosenshein N; Klein JL; Ettinger DS; Leichner PK; Order SE
    Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1671-7. PubMed ID: 6295985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy in advanced forms of carcinoma of the ovary].
    Calciati A; Clerico M; Donadio M; Giaccone G
    Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
    [No Abstract]   [Full Text] [Related]  

  • 15. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
    Sessa C; Bolis G; Valente I; Mangioni C; D'Incalci M
    Cancer Treat Rep; 1981; 65(1-2):172-3. PubMed ID: 6784922
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
    Wharton JT; Herson J; Edwards CL; Griffith AB
    Gynecol Oncol; 1982 Oct; 14(2):262-70. PubMed ID: 6813202
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
    Giannattasio M; Rizzi R; Coratelli P; Restaino A; Selvaggi L; Ferreri R; Orlando E; Ierardi GM; Granata A; Bettocchi S
    Eur J Gynaecol Oncol; 1983; 4(1):41-3. PubMed ID: 6407837
    [No Abstract]   [Full Text] [Related]  

  • 18. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.